Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG Oncology.
Mark L KaytonAaron R WeissWei XueOdion BinitieAndrea Hayes DixonRobert Lor RandallJoel I SorgerDouglas S HawkinsSheri L SpuntDian WangLynn MillionStephanie TerezakisEdwin ChoyScott H OkunoRajkumar VenkatramaniYen-Lin ChenThomas J ScharschmidtPublished in: Journal of surgical oncology (2023)
The addition of pazopanib to neoadjuvant chemotherapy and RT resulted in a higher wound complication rate following therapy of soft tissue sarcoma. The rate of grade III complications remained comparable to that reported in contemporary literature.